Citi Sticks to Their Hold Rating for Zimmer Biomet Holdings (ZBH)
In a report released today, Joanne Wuensch from Citi maintained a Hold rating on Zimmer Biomet Holdings, with a price target of $98.00.
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Wuensch covers the Healthcare sector, focusing on stocks such as Boston Scientific, Edwards Lifesciences, and GE Healthcare Technologies Inc. According to TipRanks, Wuensch has an average return of 2.3% and a 50.93% success rate on recommended stocks.
In addition to Citi, Zimmer Biomet Holdings also received a Hold from BTIG’s Ryan Zimmerman in a report issued on March 23. However, on the same day, TD Cowen maintained a Buy rating on Zimmer Biomet Holdings (NYSE: ZBH).
Based on Zimmer Biomet Holdings’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $2.24 billion and a net profit of $139.5 million. In comparison, last year the company earned a revenue of $2.02 billion and had a net profit of $239.5 million
Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ZBH in relation to earlier this year. Last month, Lori Winkler, the SVP and CHRO of ZBH sold 2,650.00 shares for a total of $250,849.00.
Read More on ZBH:
Disclaimer & DisclosureReport an Issue
- Zimmer Biomet’s RibFix Titan Study: What Chest Wall Data Could Mean for ZBH Investors
- Zimmer Biomet’s Mymobility Study: Fresh Clinical Data on a Digital Edge in Joint Replacement
- Super Micro downgraded, MongoDB upgraded: Wall Street’s top analyst calls
- Zimmer Biomet downgraded to Neutral from Buy at BTIG
- Zimmer Biomet’s New Knee Implant Study Builds a Quiet Catalyst for Long-Term Growth
